🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06636747
Recruiting Observational

High Resolution Diffusion Weighted Imaging in Prostate

NCT06636747 · tracked via the Priya Life Science China tracker
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Started
2023-08-01
Last updated
2024-10-15

Condition(s) studied

Prostate CancerProstate Disease

Study summary

hrDWI might be an alternative to cDWI for the prostate imaging.

1. increase the signal-to-noise ratio and contrast-to-noise ratio, yielding high-fidelity images with less noise in general
2. improve the diagnostic accuracy of PCa in particular than conventional DWI

Eligibility

Sex
MALE
Min age
55 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Patients who underwent standard MR scanning including T2WI, cDWI , hrDWI and respective calculated apparent diffusion coefficient (ADC) maps; 2. Complete clinical information. Exclusion Criteria: Men were excluded if they were using 5-alpha-reductase inhibitors at time of examination or has used such during the previous six months; or if they had a previous history of prostatic biopsy, prostatic surgery, or treatment for PCa

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu Recruiting
Yu-Dong Zhang Nanjing China Recruiting

More The First Affiliated Hospital with Nanjing Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06636747 on ClinicalTrials.gov ↗ ← All trials in China